Efficacy and safety of liraglutide compared to sulphonylurea during Ramadan in patients with type 2 diabetes (LIRA-Ramadan): a randomized trial.

Azar ST, Echtay A, Wan Bebakar WM, Al Araj S, Berrah A, Omar M, Mutha A, Tornøe K, Kaltoft MS, Shehadeh N

Diabetes, obesity & metabolism18 Aug 2016Cited by 36 (Europe PMC)

PMID27376711PMCIDPMC5095865DOI10.1111/dom.12733PepBankPUB-27376711

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes fasting during Ramadan, liraglutide and sulphonylurea gave similar fructosamine reductions.
In plain wordsIn adults with type 2 diabetes fasting in Ramadan, liraglutide and sulphonylurea lowered fructosamine, a short-term blood sugar marker, by similar amounts.
Peptide
Liraglutide
Outcome
No significant changeFructosamine change during Ramadan
Study
n: not reported in source
Comparator
Sulphonylurea plus metformin
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · up to 33 weeksAs given in this study (human).
Measurements
Fructosamine change
−12.8 µmol/L
liraglutide
Fructosamine change
−16.4 µmol/L
sulphonylurea
Estimated treatment difference
3.51 µmol/L
liraglutide vs sulphonylurea
Source sentences
Summary
Similar reductions in fructosamine levels were observed for both groups during Ramadan [liraglutide (-12.8 µmol/L); sulphonylurea (-16.4 µmol/L); estimated treatment difference (ETD) 3.51 µmol/L (95% CI: -5.26; 12.28); p = 0.43], despite lower fructosamine levels in the liraglutide group at start of Ramadan.
1 context sentence(design, population, supporting numbers)
Summary · context
In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or con…
Report a problemFND-2737671101
02HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes fasting during Ramadan, fewer documented symptomatic hypoglycaemic episodes occurred with liraglutide than with sulphonylurea.
In plain wordsIn adults with type 2 diabetes fasting in Ramadan, fewer low blood sugar episodes with symptoms occurred with liraglutide than with sulphonylurea.
Peptide
Liraglutide
Outcome
DecreaseDocumented symptomatic hypoglycaemic episodes
Study
n: not reported in source
Comparator
Sulphonylurea plus metformin
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg · up to 33 weeksAs given in this study (human).
Measurements
Patients with hypoglycaemia
2%
liraglutide
Patients with hypoglycaemia
11%
sulphonylurea
Source sentences
Summary
Fewer documented symptomatic hypoglycaemic episodes were reported in liraglutide-treated (2%, three subjects) versus sulphonylurea-treated patients (11%, 18 subjects).
1 context sentence(design, population, supporting numbers)
Summary · context
In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or con…
Report a problemFND-2737671102
03HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes fasting during Ramadan, no severe hypoglycaemic episodes were reported in either the liraglutide or the sulphonylurea group.
In plain wordsIn adults with type 2 diabetes fasting in Ramadan, nobody in either group had severe low blood sugar.
Peptide
Liraglutide
Outcome
No significant changeSevere hypoglycaemic episodes
Study
n: not reported in source
Comparator
Sulphonylurea plus metformin
Outcome group
Adverse events · Metabolic and weight
Studied dose
1.8 mg · up to 33 weeksAs given in this study (human).
Source sentences
Summary
No severe hypoglycaemic episodes were reported by either group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or con…
Report a problemFND-2737671103
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes fasting during Ramadan, body weight decreased more with liraglutide than with sulphonylurea.
In plain wordsIn adults with type 2 diabetes fasting in Ramadan, weight fell more with liraglutide than with sulphonylurea.
Peptide
Liraglutide
Outcome
DecreaseBody weight change during Ramadan
Study
n: not reported in source
Comparator
Sulphonylurea plus metformin
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · up to 33 weeksAs given in this study (human).
Measurements
Estimated treatment difference
−0.54 kg
liraglutide vs sulphonylurea
Source sentences
Summary
Body weight decreased more during Ramadan with liraglutide (ETD: -0.54 kg; 95% CI: -0.94;-0.14; p = 0.0091).
1 context sentence(design, population, supporting numbers)
Summary · context
In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or con…
Report a problemFND-2737671104
05HumanRandomized controlled trialSafety outcome
In adults with type 2 diabetes fasting during Ramadan, the proportion of patients with adverse events was similar between liraglutide and sulphonylurea groups.
In plain wordsIn adults with type 2 diabetes fasting in Ramadan, side effects were reported by a similar share of people with liraglutide and sulphonylurea.
Peptide
Liraglutide
Outcome
No significant changeProportion of patients with adverse events
Study
n: not reported in source
Comparator
Sulphonylurea plus metformin
Outcome group
Adverse events · Whole body
Studied dose
1.8 mg · up to 33 weeksAs given in this study (human).
Source sentences
Summary
The proportion of patients reporting adverse events was similar between groups.
1 context sentence(design, population, supporting numbers)
Summary · context
In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or con…
Report a problemFND-2737671105
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes fasting during Ramadan, liraglutide gave a greater HbA1c reduction than sulphonylurea.
In plain wordsIn adults with type 2 diabetes fasting in Ramadan, liraglutide lowered HbA1c more than sulphonylurea.
Peptide
Liraglutide
Outcome
DecreaseHbA1c reduction
Study
n: not reported in source
Comparator
Sulphonylurea plus metformin
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · up to 33 weeksAs given in this study (human).
Measurements
Estimated treatment difference
−0.59%
liraglutide vs sulphonylurea
Source sentences
Summary
Liraglutide led to greater HbA1c reduction [ETD: -0.59% (-6.40 mmol/mol), 95% CI: -0.79; -0.38%; -8.63; -4.17 mmol/mol; p < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
In this up to 33-week, open-label, active-controlled, parallel-group trial, adults [glycated haemoglobin (HbA1c) 7%-10% (53-86 mmol/mol); body mass index ≥20 kg/m(2) ; intent to fast] were randomized (1:1) ≥10 weeks before Ramadan to either switch to once-daily liraglutide (final dose 1.8 mg) or con…
Report a problemFND-2737671106

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4Results postedNCT01917656

Efficacy and Safety of Liraglutide Versus Sulphonylurea Both in Combination With Metformin During Ramadan in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 3439 Jan 2014 to 4 Sept 2014

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 24 Aug 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.